drugset / Trial / NCT02859857
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
Phase 1
Completed
86 enrolled
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. Secondarily to assess the preliminary antitumor activity of BXQ-350 in solid tumors and recurrent high grade gliomas.
Timeline
- Start
- 2016-09-01
- Primary completion
- 2019-06-17
- Completion
- 2020-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAPOSIN C (NON-GLYCOSYLATED) | Other / unclassified | 2.4 mg/kg | Intravenous |